Synonym
Elubrixin tosylate; Elubrixin (tosylate); SB-656933-AAA; SB-656933; SB 656933; SB656933; SB-656933-AAF; SB-656933 AAF; SB-656933AAF; Elubrixin
IUPAC/Chemical Name
1-(4-chloro-2-hydroxy-3-(piperazin-1-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea 4-methylbenzenesulfonate
InChi Key
CJAUWWGOABMMJX-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H17Cl2FN4O4S.C7H8O3S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24;1-6-2-4-7(5-3-6)11(8,9)10/h1-5,21,25H,6-9H2,(H2,22,23,26);2-5H,1H3,(H,8,9,10)
SMILES Code
CC1=CC=C(C=C1)S(O)(=O)=O.OC2=C(C(Cl)=CC=C2NC(=O)NC3=CC=CC(F)=C3Cl)S(=O)(=O)N4CCNCC4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
635.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary
disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J
Pharmacol Exp Ther. 2013 Oct;347(1):173-80. doi: 10.1124/jpet.112.201855. Epub
2013 Aug 2. PubMed PMID: 23912333.
2: Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL;
CF2110399 Investigators. Safety and early treatment effects of the CXCR2
antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013
May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17. PubMed PMID:
22995323.
3: Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D. LPS challenge in
healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving
CXCR1 and CXCR2. Int Immunopharmacol. 2012 Jul;13(3):225-31. doi:
10.1016/j.intimp.2012.04.008. Epub 2012 May 2. PubMed PMID: 22561413.
4: Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R.
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil
activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol.
2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x. PubMed PMID:
21426372; PubMed Central PMCID: PMC3162658.
5: Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M,
Vessey RS, Tal-Singer R, Hansel TT. A novel flow cytometric assay of human whole
blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related
to receptor expression, comparison with neutrophil shape change, and effects of a
chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20(1):52-9. Epub
2006 Jan 6. PubMed PMID: 16406722.
